• Lysosomal β-Galactosidase Staining Kit in HNSCC

  2026-08-14

  Use K2181 to visualize lysosomal acidic β-galactosidase activity in HNSCC cells and tissue sections without confusing a control stain with proof of senescence. Its polystyrene-compatible workflow, chromogenic readout, and defined troubleshooting logic support reproducible cisplatin-resistance experiments.

• Urolithin A Workflows for Mitochondrial Research

  2026-08-14

  Build reproducible Urolithin A assays around mitophagy, mitochondrial respiration, and gene-expression endpoints rather than relying on a single viability readout. This practical workflow also shows how to test mitochondrial-metabolic hypotheses in hepatic stellate cells without overstating evidence from fibrosis research.

• FAISL Stabilizes FAK Through Calpain-2 in TNBC

  2026-08-13

  The reference study identifies FAISL as a long noncoding RNA that preserves focal adhesion kinase by preventing calpain-2-mediated proteolysis. Its findings connect lncRNA-dependent control of FAK protein stability with triple-negative breast cancer adhesion, growth, and metastasis, while also illustrating why protease regulation should be evaluated alongside kinase signaling.

• Recombinant Human IL-15: Assays and Applications

  2026-08-13

  Build reproducible T-cell, NK-cell, and cytokine-response assays with a tag-free, high-purity Interleukin-15 reagent. This workflow also shows how immune-cell measurements can complement, but not replace, circuit-level studies of early life adversity and innate defensive behavior.

• NLRP3 Astrocyte Remodeling in Morphine Tolerance

  2026-08-12

  Yuan et al. identify NLRP3 inflammasome activation as a mechanistic link between repeated morphine exposure and a shift toward an A1-like reactive astrocyte profile. The study combines behavioral, molecular, and spatial measurements to show that MCC950 slows tolerance development while normalizing inflammatory and astrocyte phenotype markers.

• Pam3CSK4 TFA in Translational TLR1/2 Research

  2026-08-12

  A mechanistic and strategic guide to using Pam3CSK4 TFA as a standardized TLR1/2 agonist for innate immune profiling, inflammatory modeling, and translational maternal-neonatal research.

• PEDV Replication Depends on IMPDH-Driven Nucleotide Supply

  2026-08-11

  The reference study combines untargeted metabolomics with IMPDH2 knockdown and merimepodib treatment to show that porcine epidemic diarrhea virus (PEDV) depends on host guanine nucleotide biosynthesis. Its cell-type comparison and orthogonal validation identify IMPDH as a host-directed antiviral target while clarifying the metabolic basis of PEDV replication.

• Recombinant Human IL-15 in Neuroimmune Research

  2026-08-11

  Early life adversity research identifies oxytocin signaling in the superior colliculus as a regulator of innate defensive behavior. This thought-leadership perspective explains how Recombinant Human IL-15 can support carefully bounded immune-cell experiments that test, rather than assume, neuroimmune links.

• Extrahepatic mRNA Delivery with Virus-Mimicking Particles

  2026-08-10

  The reference study introduces a self-assembling enveloped virus-mimicking particle that combines engineered RNA-binding peptides with programmable phospholipid envelopes to overcome the hepatic bias of many mRNA delivery systems. Its lung and spleen targeting results, together with IL-12 mRNA activity in a metastatic lung tumor model, provide a useful framework for evaluating extrahepatic cytokine delivery while highlighting the need for further translational validation.

• PBA-Modified PAD4 Inhibitors Suppress Tumor NETs

  2026-08-09

  The reference study developed phenylboronic acid-modified PAD4 inhibitors, identifying Compound 5i as a tumor-targeted agent that suppresses the PAD4–H3cit–NET axis. Across sarcoma and breast cancer models, the compound reduced tumor growth and metastasis while producing a favorable safety and immune-microenvironment profile.

• CLCC1 and Herpesvirus Nuclear Egress Fusion

  2026-08-08

  A 2024 bioRxiv preprint identifies the host protein CLCC1 as essential for membrane fusion during herpes simplex virus 1 nuclear egress, distinguishing this step from viral NEC-driven budding. The findings connect herpesvirus capsid export with nuclear pore membrane insertion and provide a mechanistic basis for studying host-dependent stages of viral replication.

• MCC950 sodium in Reliable Cell Assays

  2026-08-07

  Learn how MCC950 sodium, SKU B7946, can help separate NLRP3-driven inflammatory cell death from nonspecific assay variability. This scenario-based guide covers assay design, dose selection, interpretation, and practical product-selection criteria for biomedical laboratories.

• NBC19: Applied NLRP3 Inflammasome Inhibitor Workflows & Insi

  2026-08-07

  NBC19 delivers nanomolar precision for dissecting NLRP3 inflammasome activation, enabling robust IL-1β release inhibition under diverse inflammatory stimuli. This guide bridges advanced experimental protocols with troubleshooting strategies, translating recent discoveries on macrophage-driven inflammation and metastatic microenvironments into actionable laboratory workflows.

• Maternal IL-17A Predicts Neonatal Risk in GBS Colonization

  2026-08-06

  This study identifies maternal IL-17A as a robust prognostic biomarker for neonatal invasive disease in pregnancies complicated by Group B Streptococcus (GBS) colonization. By integrating cytokine profiling and ex vivo TLR1/2 pathway activation, the work advances risk stratification in perinatal infection and informs immunological research protocols.

• Discovery and Characterization of MK 0893 as a Glucagon Rece

  2026-08-06

  The reference study details the optimization and preclinical evaluation of MK 0893, a potent, selective, and orally active glucagon receptor antagonist. Its high affinity and efficacy in reducing glucose excursions in diabetic models highlight its value for advancing type 2 diabetes research.

16395 records 1/1093 page Next 12345 下5页 Last page